Marinus Pharmaceuticals (NASDAQ:MRNS) Now Covered by StockNews.com

StockNews.com initiated coverage on shares of Marinus Pharmaceuticals (NASDAQ:MRNS) in a research report sent to investors on Sunday morning. The firm issued a hold rating on the biopharmaceutical company’s stock.

Several other brokerages also recently weighed in on MRNS. JMP Securities reaffirmed a “market perform” rating on shares of Marinus Pharmaceuticals in a report on Thursday, October 24th. HC Wainwright reiterated a “neutral” rating on shares of Marinus Pharmaceuticals in a research report on Friday, October 25th. LADENBURG THALM/SH SH cut Marinus Pharmaceuticals from a “buy” rating to a “neutral” rating in a report on Wednesday, August 14th. EF Hutton Acquisition Co. I raised Marinus Pharmaceuticals to a “strong-buy” rating in a report on Monday, September 30th. Finally, Oppenheimer upgraded shares of Marinus Pharmaceuticals from a “market perform” rating to an “outperform” rating and set a $6.00 target price on the stock in a research report on Monday, September 23rd. Nine analysts have rated the stock with a hold rating, two have given a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus target price of $6.07.

Marinus Pharmaceuticals Stock Down 12.4 %

MRNS opened at $0.30 on Friday. Marinus Pharmaceuticals has a 52 week low of $0.26 and a 52 week high of $11.26. The business has a 50 day moving average price of $1.28 and a two-hundred day moving average price of $1.34.

Marinus Pharmaceuticals (NASDAQ:MRNS) last released its quarterly earnings results on Tuesday, November 12th. The biopharmaceutical company reported ($0.42) EPS for the quarter, topping the consensus estimate of ($0.44) by $0.02. Marinus Pharmaceuticals had a negative return on equity of 7,831.35% and a negative net margin of 446.48%. The business had revenue of $8.54 million during the quarter, compared to analysts’ expectations of $8.95 million. As a group, equities analysts expect that Marinus Pharmaceuticals will post -1.92 EPS for the current fiscal year.

Institutional Trading of Marinus Pharmaceuticals

Several institutional investors and hedge funds have recently modified their holdings of MRNS. Point72 DIFC Ltd acquired a new position in shares of Marinus Pharmaceuticals during the 2nd quarter worth approximately $28,000. SG Americas Securities LLC purchased a new position in shares of Marinus Pharmaceuticals during the second quarter valued at approximately $34,000. AQR Capital Management LLC boosted its position in Marinus Pharmaceuticals by 70.3% during the second quarter. AQR Capital Management LLC now owns 31,333 shares of the biopharmaceutical company’s stock worth $37,000 after acquiring an additional 12,934 shares during the last quarter. Jacobs Levy Equity Management Inc. purchased a new stake in Marinus Pharmaceuticals in the 1st quarter worth approximately $384,000. Finally, Point72 Asia Singapore Pte. Ltd. acquired a new position in Marinus Pharmaceuticals in the 2nd quarter valued at $64,000. Hedge funds and other institutional investors own 98.80% of the company’s stock.

About Marinus Pharmaceuticals

Marinus Pharmaceuticals, Inc, a pharmaceutical company, focuses on development and commercialization of therapeutic products for patients suffering from rare genetic epilepsies and other seizure disorders. It offers ZTALMY (ganaxolone), an oral suspension for the treatment of seizures associated with cyclin-dependent kinase-like 5 deficiency disorder for adult and pediatric patient populations in acute and chronic care, and in-patient and self-administered settings.